Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Raises $1M in VC Cash for Subcellular Genetic Tools

NEW YORK, March 3 (GenomeWeb News) -- Intrexon Corporation has closed a $1 million round of private-equity financing to advance its subcellular tools and related marketing initiatives, the company said this week.

 

"This financing will enable us to expand our capabilities and offerings in the emerging market for subcellular inhibition tools," Robert Beech, Intrexon's CEO said in a statement.

 

The financing was provided by NewVa Capital Partners, a regional investment partnership managed by Third Security. NewVa last made an investment in Intrexon in May 2005.

 

Intrexon has used previous investment funds to research, develop, and validate a set of DNA vectors that target selected kinases in primary subcellular locations. These vectors are now available from the company as mDECOY kits, Intrexon said.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.